Premium
Menstrual and reproductive factors in women, genetic variation in CYP17A1 , and pancreatic cancer risk in the European prospective investigation into cancer and nutrition (EPIC) cohort
Author(s) -
Duell Eric J.,
Travier Noémie,
LujanBarroso Leila,
Dossus Laure,
BoutronRuault MarieChristine,
ClavelChapelon Françoise,
Tumino Rosario,
Masala Giovanna,
Krogh Vittorio,
Panico Salvatore,
Ricceri Fulvio,
Redondo Maria Luisa,
Dorronsoro Miren,
MolinaMontes Esther,
Huerta José M.,
Barricarte Aurelio,
Khaw KayTee,
Wareham Nick J.,
Allen Naomi E.,
Travis Ruth,
Siersema Peter D.,
Peeters Petra H.M.,
Trichopoulou Antonia,
Fragogeorgi Eirini,
Oikonomou Eleni,
Boeing Heiner,
Schuetze Madlen,
Canzian Federico,
Lukanova Annekatrin,
Tjønneland Anne,
Roswall Nina,
Overvad Kim,
Weiderpass Elisabete,
Gram Inger Torhild,
Lund Eiliv,
Lindkvist Björn,
Johansen Dorthe,
Ye Weimin,
Sund Malin,
Fedirko Veronika,
Jenab Mazda,
Michaud Dominique S.,
Riboli Elio,
BuenodeMesquita H. Bas
Publication year - 2012
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.27875
Subject(s) - menarche , medicine , european prospective investigation into cancer and nutrition , pancreatic cancer , prospective cohort study , cohort , cohort study , single nucleotide polymorphism , case control study , oncology , obstetrics , gynecology , cancer , endocrinology , biology , genetics , genotype , gene
Menstrual and reproductive factors and exogenous hormone use have been investigated as pancreatic cancer risk factors in case‐control and cohort studies, but results have been inconsistent. We conducted a prospective examination of menstrual and reproductive factors, exogenous hormone use and pancreatic cancer risk (based on 304 cases) in 328,610 women from the EPIC cohort. Then, in a case‐control study nested within the EPIC cohort, we examined 12 single nucleotide polymorphisms (SNPs) in CYP17A1 (an essential gene in sex steroid metabolism) for association with pancreatic cancer in women and men (324 cases and 353 controls). Of all factors analyzed, only younger age at menarche (<12 vs . 13 years) was moderately associated with an increased risk of pancreatic cancer in the full cohort; however, this result was marginally significant (HR = 1.44; 95% CI = 0.99–2.10). CYP17A1 rs619824 was associated with HRT use ( p value = 0.037) in control women; however, none of the SNPs alone, in combination, or as haplotypes were associated with pancreatic cancer risk. In conclusion, with the possible exception of an early age of menarche, none of the menstrual and reproductive factors, and none of the 12 common genetic variants we evaluated at the CYP17A1 locus makes a substantial contribution to pancreatic cancer susceptibility in the EPIC cohort.